APA (7th ed.) Citation

R, N., S, L., N, C., C, B., NA, K., T, A., . . . TJ, M. (2025). Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease. The journal of applied laboratory medicine, 10(6), 1580. https://doi.org/10.1093/jalm/jfaf149

Chicago Style (17th ed.) Citation

R, Nice, Lin S, Chanchlani N, Bewshea C, Kennedy NA, Ahmad T, Winyard PG, Goodhand J, and McDonald TJ. "Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease." The Journal of Applied Laboratory Medicine 10, no. 6 (2025): 1580. https://doi.org/10.1093/jalm/jfaf149.

MLA (9th ed.) Citation

R, Nice, et al. "Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease." The Journal of Applied Laboratory Medicine, vol. 10, no. 6, 2025, p. 1580, https://doi.org/10.1093/jalm/jfaf149.